Category: News

Fast Company announced its sixth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. Ossium came in at No. 56 for its company culture that encourages innovation from every corner of the organization. In addition, Ossium is a finalist on the biotech list.

“We pride ourselves in serving as a top workplace for innovators,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Our business is built on the revolutionary idea of building a vast bone marrow bank that solves a critical infrastructure problem to save thousands of lives. We’ve taken daring steps to turn this bold idea into a reality. As we scale, we continue to benefit from our organizational culture that empowers employees to blaze new trails to help advance our mission.”

The 2024 Best Workplaces for Innovators list ranks 100 winners from a variety of industries, including entertainment, biotech, consumer packaged goods, marketing, education, healthcare, and many more.
“Innovation is a global priority that cuts across all industries, and this year’s list reflects that diversity,” said Brendan Vaughan, editor in chief of Fast Company. “The top ten features four companies headquartered outside of the U.S. and includes representatives from technology, advertising, finance, biotech, pharmaceuticals, ecommerce, and the nonprofit sectors.”

Fast Company’s Best Workplaces for Innovators issue (Fall 2024) is available online now, and the print issue will be on newsstands beginning September 17, 2024. To see the complete list, go to https://www.fastcompany.com/best-workplaces-for-innovators/list.

Ossium is currently searching for innovators to fill open roles at its headquarters in San Francisco and its production facility in Indianapolis. To learn more about these open positions, visit https://ossiumhealth.com/careers/.

Kevin Caldwell, CEO di Ossium, ha recentemente visitato il NYSE ed è stato intervistato sul trading floor.

Nella conversazione di Kevin con Judy Shaw del NYSE, si è parlato delle esigenze insoddisfatte e delle iniquità dell'attuale sistema di reperimento dei donatori di midollo osseo e di come Ossium stia risolvendo questi problemi trasformando il processo di acquisizione dei donatori di midollo osseo. Come riassume Kevin, "l'idea di base è quella di prendere queste terapie cellulari, che oggi sono molto lente e di conseguenza anche molto costose, e trasformarle in una procedura scalabile che alla fine potrebbe portare benefici a decine di migliaia di pazienti in tutto il mondo ogni anno".

L'intervista si conclude con una discussione sul potenziale di Ossium di utilizzare la sua esclusiva piattaforma di banca del midollo osseo per migliorare i trattamenti in altri campi della medicina.

Scoprite l'intervista completa qui di seguito.

We’re proud to announce that we’ve been named to Forbes’ prestigious list of America’s Best Startup Employers! This recognition places us among the top 500 U.S. startups based on employee satisfaction, reputation, and company growth.

This award reflects our dedication to fostering a work environment that attracts and retains exceptional talent. Ossium employees are driven by the profound impact our work has on individuals battling life-threatening blood and immune diseases. Our team’s unwavering dedication fuels our progress towards our company mission: improving the health, vitality, and longevity of human beings through bioengineering.

See Ossium’s appearance on Forbes’ list of America’s Best Startup Employers here.

At our second appearance at the Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, Ossium CEO Kevin Caldwell presented an update on our work over the past year and outlined our vision for the future of bone marrow transplantation. 

In the presentation, Kevin explained how we’re transforming the bone marrow donation process from a service into a product. With our bone marrow bank, patients have access to a high-quality, optimally-dosed, and fully-characterized graft, eliminating the months-long wait and uncertainty associated with searching for an unrelated living donor. Our vision is to enhance the existing bone marrow registry, enabling physicians to quickly search for a matched donor in a single, comprehensive registry. Ossium’s unique advantage allows physicians to expedite patients’ treatment by immediately ordering the graft once a matched donor is found. This reimagined system allows transplants to be performed in a matter of days instead of months, improving outcomes for patients whose conditions require immediate treatment.

Kevin also provided a brief update on our GVHD study and how it fits into Ossium’s goals: “Our goal is to increase the number of procedures that can be done by making them fundamentally safer.” He described how this complements Ossium’s efforts “to increase the speed, efficiency, and quality with which [bone marrow transplants] can be done by making the bone marrow itself far easier to get.”

Lastly, Kevin introduced our newest product, OssiGraft™, a viable bone matrix allograft. He explained how working with tissue from donors that have already been screened to meet organ donation and bone marrow donation requirements results in the highest quality bone graft on the market today.

Watch the full presentation below.

Kevin Caldwell, Ossium’s CEO, Co-Founder & President, recently presented an update on our bone marrow transplant study at the 2023 Congress of the International Society for Organ Donation and Procurement. As Kevin explains in the presentation, the initiation of this clinical study is an important step toward our goal of dramatically expanding access to life-saving bone marrow transplants for blood cancer patients and enabling these procedures to be used far more broadly in the future. With our bone marrow available on-demand, patients can bypass the lengthy and uncertain process of identifying a living donor. Furthermore, patients will benefit from improved treatment outcomes due to the ability to obtain an optimized dose specific to their size and condition with lower T-cell counts.

“Our goal is to show that there’s no tradeoff between increasing the accessibility of a treatment, increasing the affordability of a treatment, and increasing the quality of a treatment. We really are shooting for all three,” summarized Kevin.

The presentation also includes an overview of Ossium’s studies of Graft-versus-Host Disease treatment and solid organ transplant tolerance induction.

Watch the full presentation below.